Harbour Investments’s Outlook Therapeutics OTLK Stock Holding History

Harbour Investments’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.53K	Buy	12,304 +2,152	+21%	+$930	﹤0.01%	3837
2025 Q4	$16K	Buy	10,152 +9,331	+1,137%	+$14.9K	﹤0.01%	2520
2025 Q3	$870	Hold	821	–	–	﹤0.01%	3431
2025 Q2	$1.31K	Sell	821 -31	-4%	-$49	﹤0.01%	3228
2025 Q1	$1.04K	Buy	852 +625	+275%	+$1.1K	﹤0.01%	3233
2024 Q4	$429	Buy	227 +100	+79%	+$411	﹤0.01%	3293
2024 Q3	$678	Buy	127 +62	+95%	+$454	﹤0.01%	3161
2024 Q2	$480	Hold	65	–	–	﹤0.01%	3092
2024 Q1	$776	Hold	65	–	–	﹤0.01%	2979
2023 Q4	$512	Hold	65	–	–	﹤0.01%	2925
2023 Q3	$287	Hold	65	–	–	﹤0.01%	2862
2023 Q2	$2.26K	Hold	65	–	–	﹤0.01%	2513
2023 Q1	$1.42K	Hold	65	–	–	﹤0.01%	2627
2022 Q4	$1.4K	Hold	65	–	–	﹤0.01%	2606
2022 Q3	$1K	Hold	65	–	–	﹤0.01%	2626
2022 Q2	$1K	Buy	+65	New	+$1.87K	﹤0.01%	2626
2021 Q4	$2K	Hold	65	–	–	﹤0.01%	2420
2021 Q3	$3K	Hold	65	–	–	﹤0.01%	3209
2021 Q2	$3K	Hold	65	–	–	﹤0.01%	3265
2021 Q1	$3K	Buy	+65	New	+$2.49K	﹤0.01%	3109

Other funds holding OTLK

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $126M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NMC

Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Harbour Investments's OTLK Position: Q1 2026 in Review

Harbour Investments increased its Outlook Therapeutics (OTLK) stake by 21% in Q1 2026, buying an estimated $930 and bringing the position to 12,304 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

Harbour Investments first reported a position in OTLK in Q1 2021 and has held it in 20 quarters since. The position peaked at $16K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

Harbour Investments held 12,304 shares of Outlook Therapeutics worth $2.53K as of Q1 2026.
Harbour Investments bought 2,152 Outlook Therapeutics shares in Q1 2026, an estimated $930.
Outlook Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3837 holding.
Harbour Investments first reported a position in Outlook Therapeutics in Q1 2021 and has held it in 20 quarters since.
Harbour Investments's Outlook Therapeutics position peaked at $16K in Q4 2025.
54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.